secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001193125-25-218508
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl's Revita maintains weight loss after GLP-1 stop; 2.5% further loss vs 10% regain in sham (p=0.014)
--------------------------------------------------------------------------------

- Revita-treated patients (n=29) lost additional 2.5% total body weight at 3 months after stopping tirzepatide; sham (n=16) regained 10% (p=0.014).
- No Revita-related SAEs or Grade II+ AEs observed; side effects mild/transient, consistent with prior studies.
- REMAIN-1 Midpoint Cohort ongoing; 6-month data expected Q1 2026.
- Pivotal cohort randomization on track for early 2026; 6-month topline data and potential PMA filing in H2 2026.
- Results provide first randomized, blinded evidence of durable drug-free weight maintenance post-GLP-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312525218508/0001193125-25-218508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312525218508/d870124d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-218508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer